

TOOKAD® : Welchen Stellenwert hat diese Technik 2021?

Angelika Borkowetz

Literatur

1. Krebsregisterdaten, R.K.I.Z.f., Krebs in Deutschland für 2015/2016. 2019.
2. Pompe, RS, et al., Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. *Prostate*, 2017. 77: 686–693.
3. Burnet, KL, et al., Does active surveillance for men with localized prostate cancer carry psychological morbidity? *BJU Int* 2007; 100: 540–543.
4. Klotz, L, et al., Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol* 2015; 33: 272–277.
5. Tosoian, JJ, et al., Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. *Eur Urol* 2020; 77: 675–682.
6. van der Poel, HG, et al., Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol* 2018; 74: 84-91.
7. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., L. AWMF): S3-Leitlinie Prostatakarzinom, 2021, AWMF Registernummer:, and h.w.l.-o.d.l.p. 043/022OL. 12.05.2021].
8. Arumainayagam, N, et al., Photodynamic therapy for focal ablation of the prostate. *World J Urol* 2010; 28: 571–576.
9. authorisation-details-section., h.w.e.e.e.m.h.E.t.-. (abgerufen am: 05.05.2021).
10. <https://www.g-ba.de/bewertungsverfahren/verfahren-137h/22>. (abgerufen am: 05.05.2019).
11. Azzouzi, AR, Emberton M, and P.C.M.s. investigators, Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply. *Lancet Oncol* 2017; 18: e188.
12. Chelly, S, et al., Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. *Asian J Androl* 2020; 22: 454–458.
13. Flegar, L, et al., Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. *Eur Urol Focus* 2021.
14. Pierrard, V, et al., Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. *J Urol* 2019; 201: 315–321.
15. Marra, G, et al., Salvage Local Treatments After Focal Therapy for Prostate Cancer. *Eur Urol Oncol* 2019; 2: 526–538.
16. von Hardenberg, J, et al., Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer. *World J Urol* 2021.
17. Rodriguez-Rivera, JA, et al., Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. *Actas Urol Esp* 2018; 42: 632–638.